Licensing · Latin America · Announced 24 Oct 2026

Orchid Pharma → Laboratorio Libra

Orchid Pharma licensed its antibiotic Exblifep to Uruguay's Laboratorio Libra for nine Latin American markets, an opportunity Orchid puts at about US$80 million over ten years, with Orchid supplying finished product.

Parties: Orchid Pharma (India) → Laboratorio Libra (Uruguay)

Deal type
Licensing
Value
$80m
Territory
Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay, Uruguay
Therapeutic area
Infectious Disease
Asset
Exblifep (cefepime/enmetazobactam)
Announced
24 Oct 2026

Our analysis

Why this matters

Orchid Pharma announced on 24 October 2026 a licensing and supply agreement with Laboratorio Libra for Exblifep (cefepime/enmetazobactam), a carbapenem-sparing antibiotic for complicated urinary tract infections and hospital- and ventilator-acquired pneumonia caused by Gram-negative pathogens. Libra gets exclusive rights to register, import and market the product in Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay and Uruguay. Orchid will manufacture and supply the finished product.

Orchid describes the deal as a potential commercial opportunity of about US$80 million over the first 10 years, based on projected demand. Upfront and milestone terms were not disclosed. Launch in each market depends on national regulatory approval; Exblifep already holds FDA and EMA approvals.

The full analysis is free to read with a work email on this page.

Source: Equitybulls (Orchid Pharma release)

Latest deals

All Latin America deals → · All licensing deals → · Browse all emerging-market pharma deals →